List of Excipients in Branded Drug MEPIVACAINE HYDROCHLORIDE

Generic Drugs Containing MEPIVACAINE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Henry Schein Inc	mepivacaine hydrochloride	0404-6730	SODIUM CHLORIDE
Henry Schein Inc	mepivacaine hydrochloride	0404-6730	SODIUM HYDROXIDE
Henry Schein Inc	mepivacaine hydrochloride	0404-6730	WATER
Safco Dental Supply Co	mepivacaine hydrochloride	67239-0201	SODIUM CHLORIDE
Safco Dental Supply Co	mepivacaine hydrochloride	67239-0201	SODIUM HYDROXIDE

What are the Most Frequently-Used Excipients in MEPIVACAINE HYDROCHLORIDE?

# Of NDCs	Excipient
2	SODIUM CHLORIDE
2	SODIUM HYDROXIDE
2	WATER

Mepivacaine Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: August 22, 2026

Mepivacaine hydrochloride is an established, generic local anesthetic with limited active-ingredient patent value and low formulation complexity. Its commercial opportunity lies in differentiated injectable presentations, preservative-free products, dental delivery systems, ready-to-use packaging, supply reliability, and specialty formulations for hospitals, ambulatory surgery centers, dental practices, and veterinary users. Excipient selection must protect chemical stability, sterility, injection comfort, container compatibility, and regulatory simplicity.

What is the commercial profile of mepivacaine hydrochloride?

Mepivacaine hydrochloride is an amide local anesthetic used for infiltration, peripheral nerve block, epidural administration, and dental anesthesia. It is available in injectable concentrations that commonly include 1%, 1.5%, 2%, and 3%, depending on the product and indication.[1-4]

Attribute	Commercial relevance
Active ingredient	Mepivacaine hydrochloride
Drug class	Amide local anesthetic
Main dosage form	Sterile injectable solution
Common concentrations	1%, 1.5%, 2%, 3%
Typical markets	Dental, hospital, ambulatory surgery, emergency care, veterinary
Preservative status	Preservative-free and multidose presentations exist
Vasoconstrictor combination	Mepivacaine with levonordefrin in selected dental products
Patent position	Mature generic molecule with limited active-ingredient exclusivity
Primary differentiation	Excipients, container, dose format, device, supply, and labeling

Mepivacaine has an important dental advantage over some alternative local anesthetics because plain mepivacaine can provide useful anesthesia without a vasoconstrictor. This supports use in patients for whom epinephrine or another sympathomimetic is undesirable, although product selection remains clinically specific.[2,3]

What excipients are used in mepivacaine hydrochloride injections?

The core formulation is generally a simple aqueous solution containing mepivacaine hydrochloride, water for injection, and pH-adjusting agents. Sodium chloride may be included to adjust tonicity. Product-specific labels control the precise composition.[1-4]

Typical excipient architecture

Formulation component	Function	Strategy considerations
Water for injection	Vehicle	Must meet parenteral water quality requirements
Hydrochloric acid	pH adjustment	Supports pH control and salt-form stability
Sodium hydroxide	pH adjustment	Used where required to establish target pH
Sodium chloride	Tonicity adjustment	May improve osmolality and injection tolerability
Methylparaben or related preservative	Multidose antimicrobial protection	Increases preservative-related labeling and compatibility requirements
Nitrogen overlay	Oxygen reduction during manufacture or filling	A process aid rather than a conventional formulation excipient
Levonordefrin	Pharmacologically active vasoconstrictor	Applies only to combination products, not a conventional excipient

The preferred development strategy for a new mepivacaine injectable is usually a preservative-free, single-dose formulation unless a multidose package creates a clear commercial advantage. Preservatives can complicate dental and neuraxial positioning because some clinical settings favor preservative-free products.

Which excipient strategy is best for mepivacaine hydrochloride?

A commercially attractive baseline is a sterile, preservative-free, isotonic aqueous solution with tightly controlled pH and low extractables from the container-closure system.

Recommended baseline formulation

A practical starting design would include:

1. Mepivacaine hydrochloride at the target concentration.
2. Water for injection.
3. Sodium chloride only if needed to meet osmolality targets.
4. Minimal acid or base for pH adjustment.
5. No antimicrobial preservative in single-dose presentations.
6. A low-reactivity container, such as a glass cartridge, vial, or polymeric syringe qualified for the formulation.

The formulation should avoid unnecessary buffers unless stability data demonstrate a specific benefit. A buffer can increase ionic strength, alter osmolality, introduce compatibility risks, and expand the analytical package without creating a clear clinical advantage.

Why a low-excipient formulation is commercially useful

Mepivacaine hydrochloride does not require a complex lipid, suspension, emulsion, or polymer delivery system. A short excipient list can reduce:

• Extractables and leachables risk.
• Sterilization and container-closure complexity.
• Regulatory review burden.
• Labeling concerns for sensitive patient populations.
• Manufacturing cost.
• Risk of incompatibility with dental cartridges and injection devices.

The main technical challenge is not solubilization. It is long-term control of pH, degradation, particulate matter, sterility, container compatibility, and dose uniformity.

What formulation patents protect mepivacaine hydrochloride products?

Mepivacaine hydrochloride is an old small molecule. Its active-ingredient patent estate is no longer the primary commercial barrier. Product protection is more likely to come from formulation-specific claims, delivery devices, manufacturing processes, or combination products.

Potentially protectable technical features include:

Protection area	Patent potential	Commercial value
Novel mepivacaine salt or solid form	Low	Low unless it improves stability or processing
Preservative-free injectable solution	Limited	Moderate if supported by stability or usability advantages
pH-controlled formulation	Limited to moderate	Useful if it solves degradation or pain-on-injection issues
Premixed mepivacaine and vasoconstrictor	Low to moderate	Relevant to dental products
Prefilled syringe or dental cartridge	Moderate	Can create device and convenience differentiation
Low-extractables container system	Moderate	Valuable for hospital and regulatory positioning
Extended-stability formulation	Moderate	Supports inventory, tender, and international distribution
Sustained-release depot system	Higher technical value	Requires substantial clinical and regulatory investment
Manufacturing process	Moderate	Useful for quality, yield, and supply protection
Combination with another anesthetic	Moderate	Commercial value depends on clinical benefit

A conventional mepivacaine solution with standard excipients is unlikely to support strong composition-of-matter protection. A defensible patent program would need to link the excipient system to a measurable technical result, such as improved stability, reduced injection pain, reduced impurity formation, improved cartridge compatibility, or longer shelf life.

What FDA regulatory status and Orange Book issues apply?

Mepivacaine hydrochloride injectable products are regulated as prescription drug products. Product-specific labeling identifies the route, concentration, dosage form, warnings, contraindications, and excipient composition.[1-4]

The main regulatory pathways are:

• ANDA approval for a therapeutically equivalent generic injectable.
• NDA or 505(b)(2) development for a materially differentiated formulation, delivery system, or combination.
• Drug-device combination review where a prefilled syringe, cartridge, autoinjector, or other delivery system contributes materially to the product.
• International national or decentralized procedures outside the United States.

For a standard generic injectable, the commercial burden is driven by pharmaceutical equivalence, sterility assurance, container-closure qualification, extractables and leachables, stability, particulate control, and manufacturing reliability. A novel excipient or nontraditional delivery system could move the product away from a straightforward ANDA strategy.

Orange Book value is limited for an old generic anesthetic unless a sponsor has listed a qualifying formulation, method-of-use, or device-related patent. The key commercial question is therefore usually not whether mepivacaine has active-ingredient exclusivity, but whether a specific branded presentation has enforceable formulation or device rights.

When does mepivacaine hydrochloride lose exclusivity?

Mepivacaine hydrochloride lost meaningful active-ingredient exclusivity decades ago. Generic competition is established, and standard injectable products are generally exposed to ANDA competition.

Exclusivity category	Expected position
New chemical entity exclusivity	Expired
Active-ingredient patent	Expired or commercially irrelevant
Standard injectable formulation exclusivity	Generally unavailable
Orphan exclusivity	Not a central feature of the product
Pediatric exclusivity	Not a principal commercial barrier
Formulation or device exclusivity	Possible only for a specific differentiated product
Biosimilar exclusivity	Not applicable

There is no biosimilar risk because mepivacaine hydrochloride is a chemically synthesized small molecule, not a biologic. The relevant competitive threat is generic injectable substitution and branded-generic price competition.

What generic entry risks exist for mepivacaine hydrochloride?

Generic entry risk is high for standard vial and cartridge presentations. The molecule is well characterized, the formulation is relatively simple, and clinical use is established.

The main risks to a new entrant are operational rather than patent-based:

• Injectable manufacturing capacity.
• Sterility failures or inspection findings.
• Shortages of glass cartridges, stoppers, or specialty components.
• Product-specific extractables and leachables work.
• Hospital purchasing pressure.
• Dental distributor concentration.
• Contract manufacturing dependence.
• State and institutional formulary substitution.
• Price erosion after multiple ANDA entrants.

A differentiated product can reduce direct price comparability by using a prefilled syringe, a high-throughput dental cartridge, a preservative-free multidose alternative, or a supply-secure presentation designed for hospital procurement.

What commercial opportunities exist for mepivacaine hydrochloride?

Preservative-free dental cartridges

A preservative-free 3% mepivacaine cartridge is the clearest established opportunity. Dental practitioners use cartridge-based delivery systems, and product reliability, breakage resistance, plunger performance, and consistent aspiration behavior can influence purchasing.

Commercial differentiation can focus on:

• Consistent cartridge dimensions.
• Low breakage rates.
• Reliable plunger movement.
• Clear labeling and color coding.
• Long shelf life.
• Reduced particulate risk.
• Stable supply during shortages.

Ready-to-use hospital syringes

A prefilled syringe containing a standard mepivacaine concentration could reduce preparation steps in ambulatory procedures and emergency settings. The product would compete on medication-error reduction, workflow efficiency, and waste reduction rather than on molecule-level differentiation.

The principal development barriers are device compatibility, dose accuracy, sterilization strategy, extractables and leachables, and human-factors validation.

Preservative-free multidose packaging

A multidose preservative-free product could target institutions that want reduced preservative exposure but need repeated access to the same product. This opportunity is technically more demanding because the package and aseptic-use controls must support repeated withdrawals without relying on an antimicrobial preservative.

Veterinary presentations

Mepivacaine is used in veterinary practice, particularly for local and regional anesthesia. Veterinary products may support differentiated vial sizes, lower acquisition cost, simplified labeling, and distribution through animal-health channels. The regulatory pathway and market access requirements must be evaluated separately from human prescription products.

International supply and shortage mitigation

Injectable local anesthetics have experienced periodic supply constraints across markets. A manufacturer with reliable sterile capacity, dual-source raw materials, and multiple package sizes can compete effectively in tenders and distributor contracts.

A second-source strategy can have more commercial value than a new excipient system if hospitals prioritize uninterrupted supply.

How does mepivacaine compare with lidocaine and bupivacaine?

Factor	Mepivacaine HCl	Lidocaine HCl	Bupivacaine HCl
Core use	Dental and regional anesthesia	Broad local anesthesia and antiarrhythmic use	Longer-duration regional anesthesia
Plain formulation value	High in dental practice	High	High
Vasoconstrictor combinations	Levonordefrin and selected combinations	Commonly epinephrine combinations	Commonly epinephrine combinations
Duration	Intermediate	Short to intermediate	Long
Formulation complexity	Low	Low to moderate	Low to moderate
Commercial differentiation	Packaging, preservative status, supply	Concentration, combinations, delivery	Duration, liposomal or extended-release systems
Patent opportunity	Limited for standard products	Limited for standard products	Higher for advanced extended-release products
Biosimilar risk	None	None	None

Mepivacaine is less attractive than bupivacaine for advanced sustained-release investment but can be attractive for a focused dental or hospital delivery product. Its commercial position depends on workflow and availability rather than a novel pharmacologic profile.

What manufacturing and intellectual-property barriers matter most?

The most meaningful barriers are:

1. Sterile manufacturing capability.
2. Consistent filling into cartridges, vials, or syringes.
3. Control of pH and degradation impurities.
4. Container-closure integrity.
5. Low particulate burden.
6. Reliable supply of pharmaceutical-grade mepivacaine hydrochloride.
7. Device compatibility.
8. Regulatory documentation for preservative-free claims.
9. Protection against product substitution in institutional contracts.

A patent strategy should focus on a specific technical advantage. Broad claims covering mepivacaine hydrochloride in water, sodium chloride, or conventional pH-adjusted solution are likely to face validity and obviousness challenges. Narrow claims tied to a defined impurity profile, container, stability threshold, delivery device, or manufacturing parameter are more defensible.

Which companies are positioned in the mepivacaine market?

The market includes established dental-anesthetic manufacturers, generic injectable manufacturers, and regional suppliers. Septodont has a significant dental anesthetic presence, including mepivacaine products such as Scandonest in various markets.[3] Other suppliers market generic mepivacaine hydrochloride injections through hospital and specialty pharmaceutical channels.[1,2,4]

Competitive strength depends on:

• Dental distributor access.
• Hospital contracting.
• Sterile manufacturing scale.
• Product availability.
• Cartridge and vial capacity.
• Regulatory registrations across jurisdictions.
• Ability to maintain supply during shortages.

Revenue data for mepivacaine alone are generally not disclosed consistently by manufacturers. The addressable opportunity is best evaluated through unit volume, procedure demand, institutional contracts, dental channel penetration, and price per cartridge or vial.

What patent litigation and Paragraph IV risks affect the product?

Standard mepivacaine hydrochloride products face limited patent litigation risk because the molecule and basic injectable presentations are mature. Paragraph IV risk is most relevant when a branded or specialty product relies on a later-added formulation, device, combination, or method-of-use patent.

Potential litigation triggers include:

• A branded preservative-free formulation.
• A proprietary prefilled syringe.
• A cartridge delivery system.
• A sustained-release formulation.
• A combination with a vasoconstrictor or another anesthetic.
• A patent claiming a specific stability or impurity profile.

For a conventional generic vial or dental cartridge, the principal launch risk is regulatory approval, manufacturing readiness, and market pricing rather than patent settlement. No biosimilar litigation framework applies.

What is the best commercial development path?

The strongest near-term strategy is a preservative-free, ready-to-use product in a high-demand concentration and package format, supported by:

• Simple aqueous excipients.
• Strong container-closure data.
• Long shelf life.
• Multiple package sizes.
• Dental and hospital channel access.
• Dual-source manufacturing.
• A narrow patent position around the device, container, or stability advantage.

An advanced sustained-release product could produce higher differentiation but would require clinical development and would compete with more sophisticated local-anesthetic technologies. It is a higher-risk strategy than improving the standard injectable presentation.

Key Takeaways

• Mepivacaine hydrochloride is a mature generic local anesthetic with no meaningful active-ingredient exclusivity.
• The preferred baseline is a preservative-free aqueous injectable with minimal excipients.
• Sodium chloride may be used for tonicity; hydrochloric acid or sodium hydroxide may be used for pH adjustment.
• Dental cartridges, prefilled syringes, and supply-secure hospital presentations offer the strongest commercial opportunities.
• Patent value is more likely to arise from packaging, devices, stability, manufacturing, or delivery systems than from the formulation concept alone.
• Generic entry risk is high for standard vials and cartridges.
• Biosimilar risk is not applicable.
• The principal commercial barriers are sterile manufacturing, device compatibility, procurement access, and supply reliability.

FAQs

Can mepivacaine hydrochloride be formulated without preservatives?

Yes. Single-dose preservative-free mepivacaine hydrochloride injections and dental products are commercially established. The package must provide appropriate sterility and container-closure assurance.

Is sodium chloride required in every mepivacaine injection?

No. Sodium chloride is product-specific and may be included to adjust tonicity. The final formulation must meet applicable osmolality, stability, and injection-tolerability requirements.

Can a new mepivacaine product obtain a patent?

Potentially, but standard mepivacaine hydrochloride solutions are unlikely to support broad, strong claims. The most credible opportunities involve a specific device, container, stability profile, manufacturing process, or advanced delivery system.

Is mepivacaine with levonordefrin protected by a separate patent estate?

Any current protection would depend on the specific product, jurisdiction, formulation, and listed patents. The combination itself is an established dental presentation, so broad exclusivity should not be assumed.

Would a prefilled mepivacaine syringe qualify as a 505(b)(2) product?

It may, depending on the extent of formulation, device, labeling, and clinical differences from reference products. A conventional generic syringe presentation could instead fit an ANDA strategy if it meets applicable equivalence requirements.

References

1. U.S. Food and Drug Administration. (n.d.). Mepivacaine hydrochloride injection prescribing information. DailyMed.

2. U.S. Food and Drug Administration. (n.d.). Carbocaine and Polocaine product labeling. DailyMed.

3. Septodont. (n.d.). Scandonest plain and Scandonest special product information. Septodont.

4. U.S. Pharmacopeia. (2024). Mepivacaine hydrochloride monograph. United States Pharmacopeial Convention.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.